Hyaluronidase and trastuzumab
Generic name: Hyaluronidase And Trastuzumab
Brand names: Herceptin Hylecta
Dosage form: subcutaneous solution (10,000 units-600 mg/5 mL)
Drug class:
HER2 inhibitors
Usage of Hyaluronidase and trastuzumab
Hyaluronidase is a genetically designed protein. Trastuzumab is a cancer medicine.
Hyaluronidase and trastuzumab is a combination medicine used to treat certain types of breast cancer.
Hyaluronidase and trastuzumab may also be used for purposes not listed in this medication guide.
Hyaluronidase and trastuzumab side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver right away if you feel dizzy, nauseated, feverish, chilled, short of breath, or if you have diarrhea, a rash, chest pain, swelling in your face, or trouble breathing.
Hyaluronidase and trastuzumab may cause serious side effects. Call your doctor at once if you have:
Common side effects of hyaluronidase and trastuzumab may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Hyaluronidase and trastuzumab
This medicine can cause heart failure, especially if you have heart disease or if you are also receiving certain other cancer medicines (such as daunorubicin, doxorubicin, Epirubicin, or idarubicin)
Tell your doctor if you have ever had:
Do not use hyaluronidase and trastuzumab if you are pregnant. This medicine can cause injury or death to the unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 7 months after your last dose.
If you become pregnant while using this medicine or within 7 months after you stop, your name may be listed on a pregnancy registry to track the effects of hyaluronidase and trastuzumab on the baby.
It may not be safe to breast-feed while using this medicine and for up to 7 months after your last dose. Ask your doctor about any risk.
Relate drugs
- Ado-trastuzumab emtansine
- Enhertu
- Fam-trastuzumab deruxtecan
- Fam-trastuzumab deruxtecan-nxki
- Herceptin
- Herceptin Hylecta
- Herzuma
- Herzuma (Trastuzumab Intravenous)
- Herzuma (Trastuzumab-pkrb Intravenous)
- Hyaluronidase and trastuzumab
- Hyaluronidase, pertuzumab, and trastuzumab
- Kadcyla
- Margenza
- Margetuximab
- Margetuximab-cmkb
- Ogivri
- Ogivri (Trastuzumab Intravenous)
- Ogivri (Trastuzumab-dkst Intravenous)
- Ontruzant
- Ontruzant (Trastuzumab Intravenous)
- Ontruzant (Trastuzumab-dttb Intravenous)
- Perjeta
- Pertuzumab
- Pertuzumab, trastuzumab, and hyaluronidase-zzxf
- Phesgo
- Trastuzumab
- Trastuzumab and hyaluronidase-oysk
- Trastuzumab-anns
- Trastuzumab-dkst
- Trastuzumab-dttb
- Trastuzumab-pkrb
- Trazimera
- Tucatinib
- Tukysa
How to use Hyaluronidase and trastuzumab
Usual Adult Dose for Breast Cancer:
10,000 units/600 mg (10,000 units hyaluronidase/600 mg trastuzumab) suBCutaneously over 2 to 5 minutes every 3 weeksDuration of therapy:-Treat adjuvant breast cancer for 52 weeks or until disease recurrence, whichever occurs first; extending therapy beyond one year is not recommended.-Treat metastatic breast cancer until progression of disease.Comments:-If a dose is missed, it should be given as soon as possible, and the next dose should be given 3 weeks later. Uses:-For adjuvant treatment of adults with HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel OR as with docetaxel and Carboplatin OR as a single agent following multi-modality anthracycline based therapy-For metastatic breast cancer in combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer OR as a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Warnings
hyaluronidase and trastuzumab can cause heart failure, especially if you have heart disease or if you are also receiving certain other cancer medicines.
Some side effects may occur during the injection. Tell your caregiver right away if you feel dizzy, nauseated, feverish, chilled, short of breath, or if you have diarrhea, a rash, chest pain, swelling in your face, or trouble breathing.
What other drugs will affect Hyaluronidase and trastuzumab
Other drugs may affect hyaluronidase and trastuzumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Hyaluronidase and trastuzumab can have long lasting effects on your heart, especially if you receive other cancer medicines. For at least 7 months after your last dose of trastuzumab, tell any doctor who treats you that you have used hyaluronidase and trastuzumab.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions